# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Goldman Sachs analyst Bruno Amorim maintains Ultrapar Participacoes (NYSE:UGP) with a Neutral and raises the price target fr...
Goldman Sachs analyst Bruno Amorim maintains Ultrapar Participacoes (NYSE:UGP) with a Neutral and raises the price target fr...
As of Nov. 15, 2023, three stocks in the energy sector could be flashing a real warning to investors who value momentum as a ke...
Goldman Sachs analyst Bruno Amorim maintains Ultrapar Participacoes (NYSE:UGP) with a Neutral and raises the price target fr...
Jefferies analyst Alejandro Demichelis initiates coverage on Ultrapar Participacoes (NYSE:UGP) with a Underperform rating an...
Needham cut the price target for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) from $60 to $53. Needham analyst Gil Blum main...
Goldman Sachs analyst Bruno Amorim downgrades Ultrapar Participacoes (NYSE:UGP) from Buy to Neutral and lowers the price tar...